Asel Sartbaeva Email

Co-founder and CEO . EnsiliTech

Current Roles

Employees:
13
Revenue:
$1M
About
Our novel ensilication technology exploits the growth of protective silica nanoshells on the surface of vaccine components, to prevent degredation which can lead to vaccine spoilage. Once applied, our vaccines can be stored and transported without the need for cold chain infrastructure, preventing wastage, improving shelf-life and increasing vaccine accessibility globally. Ensilication can be applied to protect a wide variety of biomolecules against environmental degradation, eliminating the need for cold chain requirements and propelling the development of more oral and mucosal delivery of vaccines and therapeutics for both animals and humans. We are actively looking for partners to work with us in developing new technologies free from the reliance on the cold chain. Please don't hesitate to contact us if you're interested in finding out more about us and the problem of cold chain dependent vaccines.
EnsiliTech Address
Department of Chemistry, University of Bath
Bath, Bath
EnsiliTech Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.